Key Points
-
A number of treatments are available for hepatocellular carcinoma (HCC), and their allocation—as well as disease prognosis—is influenced by tumour stage and the degree of liver-function impairment
-
The current definition of intermediate-stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage B) is extensive multifocal disease confined to the liver, with preserved liver function and no cancer-related symptoms
-
Transarterial chemoembolization (TACE) is considered the standard treatment for intermediate-stage HCC in patients with preserved liver function and no cancer-related symptoms
-
Major efforts have been made to improve outcomes among patients treated with TACE; accurate technique together with appropriate patient selection is key to obtaining the best results
-
Sorafenib, the only systemic treatment associated with a survival benefit in HCC, should be considered for patients with BCLC stage B HCC who are not eligible for TACE
-
Radioembolization has antitumoural efficacy in patients with intermediate-stage HCC, but evidence of survival benefit has not been presented and is awaited
Abstract
Hepatocellular carcinoma (HCC)—closely associated with liver cirrhosis and, in fact, the main cause of death in patients with such disease—is now recognized as one of the most-prevalent and lethal neoplasms worldwide. Prognosis and allocation of the multiple available treatment options for patients with HCC are influenced not only by tumour stage, but also by the degree of liver-function impairment. Therefore, accurate assessment and classification of disease is important for patient management. According to the Barcelona Clinic Liver Cancer (BCLC) algorithm, intermediate-stage HCC is defined as extensive multifocal disease without vascular invasion in patients with preserved liver function and absence of cancer-related symptoms; in this context, transarterial chemoembolization (TACE) is considered the standard treatment. The use of drug-eluting beads has enabled standardization of this procedure, resulting in higher reproducibility and tolerability of the treatment. Nevertheless, not all patients with intermediate-stage HCC are good candidates for TACE and, for such patients in whom TACE is not appropriate or has failed, other treatments can be considered, including sorafenib. Radioembolization is a promising alternative that deserves further prospective studies. Herein, we review the current approaches used to accurately stratify patients with intermediate-stage HCC and subsequently allocate the most-appropriate treatments. The key developments in therapeutic strategies are also discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012).
El-Serag, H. B. & Mason, A. C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745–750 (1999).
WHO International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Prevalence and Mortality Worldwide in 2012 [online], (2014).
Sangiovanni, A. et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43, 1303–1310 (2006).
Cabibbo, G. et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51, 1274–1283 (2010).
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28, 751–755 (1998).
Vauthey, J. N. et al. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 20, 1527–1536 (2002).
Kudo, M. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40, 1396–1405 (2004).
Tateishi, R. et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54, 419–425 (2005).
Hsu, C. Y. et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J. Hepatol. 53, 108–117 (2010).
Forner, A., Reig, M. E., de Lope, C. R. & Bruix, J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 30, 61–74 (2010).
Yau, T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146, 1691–1700 (2014).
Collette, S. et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann. Oncol. 19, 1117–1126 (2008).
Huitzil-Melendez, F. D. et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J. Clin. Oncol. 28, 2889–2895 (2010).
Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646–649 (1973).
Sorensen, J. B., Klee, M., Palshof, T. & Hansen, H. H. Performance status assessment in cancer patients. An inter-observer variability study. Br. J. Cancer 67, 773–775 (1993).
Bruix, J. & Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022 (2011).
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).
D'Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231 (2006).
Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749–1761 (2014).
Cillo, U. et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J. Hepatol. 40, 124–131 (2004).
Marrero, J. A. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41, 707–716 (2005).
Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329–338 (1999).
Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734–1739 (2002).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
Ferenci, P. et al. Hepatocellular carcinoma (HCC): a global perspective. J. Clin. Gastroenterol. 44, 239–245 (2010).
Verslype, C., Rosmorduc, O. & Rougier, P. Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii41–vii48 (2012).
Beaugrand, M. et al. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an International randomized double-blind placebo-controlled study in 747 patients. J. Hepatol. 42, 17A (2005).
Bruix, J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J. Hepatol. 57, 821–829 (2012).
Llovet, J. M. et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29, 62–67 (1999).
Bolondi, L. et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin. Liver Dis. 32, 348–359 (2012).
Livraghi, T. et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197, 101–108 (1995).
Imamura, H. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38, 200–207 (2003).
Ikai, I. et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101, 796–802 (2004).
Todo, S. & Furukawa, H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann. Surg. 240, 451–459 (2004).
Takayasu, K. et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 131, 461–469 (2006).
Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 27, 3027–3035 (2009).
N'Kontchou, G. et al. Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50, 1475–1483 (2009).
Merani, S. et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J. Hepatol. 55, 814–819 (2011).
Duvoux, C. et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 143, 985–986 (2012).
Llovet, J. M. et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18, 2290–2300 (2012).
Chevret, S. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J. Hepatol. 31, 133–141 (1999).
Leung, T. W. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94, 1760–1769 (2002).
Kitai, S. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 75 (Suppl. 1), 83–90 (2008).
Camma, C. et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment. Pharmacol. Ther. 28, 62–75 (2008).
Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429–442 (2003).
Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164–1171 (2002).
Kudo, M. et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 29, 339–364 (2011).
Benson, A. B. et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J. Natl Compr. Canc. Netw. 7, 350–391 (2009).
Omata, M. et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 4, 439–474 (2010).
Lencioni, R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 52, 762–773 (2010).
Raoul, J. L. et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70, 585–590 (1992).
Kwok, P. C. et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J. Hepatol. 32, 955–964 (2000).
Bruix, J. et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27, 1578–1583 (1998).
Varela, M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46, 474–481 (2007).
Furuse, J. et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am. J. Clin. Oncol. 26, 159–164 (2003).
Lee, K.-H. et al. Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver. J. Vasc. Interv. Radiol. 19, 1065–1069 (2008).
Chen, M. S. et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J. Gastroenterol. 8, 74–78 (2002).
[No authors listed] A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N. Engl. J. Med. 332, 1256–1261 (1995).
Pelletier, G. et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J. Hepatol. 29, 129–134 (1998).
Oliveri, R. S., Wetterslev, J. & Gluud, C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Systematic Reviews, Issue 3. Art. No.: CD004787. http://dx.doi.org/10.1002/14651858.CD004787.pub2.
Ray, C. E. Jr, Haskal, Z. J., Geschwind, J. F. & Funaki, B. S. The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. J. Vasc. Interv. Radiol. 22, 1693–1696 (2011).
Forner, A., Llovet, J. M. & Bruix, J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J. Hepatol. 56, 984–986 (2012).
Raoul, J. et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev. 37, 212–220 (2011).
Namur, J. et al. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J. Vasc. Interv. Radiol. 21, 259–267 (2010).
Poon, R. T. et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol. 5, 1100–1108 (2007).
Lammer, J. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Interv. Radiol. 33, 41–52 (2010).
Burrel, M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J. Hepatol. 56, 1330–1335 (2012).
Malagari, K. et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc. Interv. Radiol. 35, 1119–1128 (2012).
Takayasu, K. et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am. J. Roentgenol. 194, 830–837 (2010).
Takayasu, K. et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J. Hepatol. 56, 886–892 (2012).
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205–216 (2000).
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Forner, A. et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115, 616–623 (2008).
Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421–430 (2001).
Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698–711 (2008).
Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52–60 (2010).
Riaz, A. et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303, 1062–1069 (2010).
Bargellini, I. et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur. J. Radiol. 82, e212–e218 (2013).
Golfieri, R. et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 53, 1580–1589 (2011).
Riaz, A. et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J. Hepatol. 54, 695–704 (2011).
Gillmore, R. et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J. Hepatol. 55, 1309–1316 (2011).
Memon, K. et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141, 526–535 (2011).
Prajapati, H. J. et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann. Oncol. 24, 965–973 (2013).
Choi, J. et al. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. J. Hepatol. 60, 1212–1218 (2014).
Lencioni, R. et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J. Hepatol. 49, 217–222 (2008).
Peng, Z.-W. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J. Clin. Oncol. 31, 426–432 (2013).
Wang, W., Shi, J. & Xie, W.-F. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 30, 741–749 (2010).
Ni, J., Liu, S., Xu, L., Sun, H. & Chen, Y. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J. Cancer Res. Clin. Oncol. 139, 653–659 (2013).
Lu, Z. et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur. J. Gastroenterol. Hepatol. 25, 187–194 (2013).
Lencioni, R. et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc. Intervent. Radiol. 35, 980–985 (2012).
Park, J.-W. et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 33, 327–337 (2013).
Sergio, A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914–921 (2008).
Sieghart, W. et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57, 2261–2273 (2013).
Hucke, F. et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J. Hepatol. 60, 118–126 (2014).
Bruix, J. et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 54, 2238–2244 (2011).
Dufour, J. F. et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15, 1198–1204 (2010).
Lencioni, R. et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial [abstract]. J. Clin. Oncol. 30, LBA154 (2012).
Chung, Y. H. et al. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int. J. Cancer 132, 2448–2458 (2013).
Kudo, M. et al. A randomized, doubled-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results [abstract O–022]. Presented at the 7th ILCA Annual Conference 2013.
Yeo, W. et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97, 1532–1538 (2005).
Louafi, S. et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109, 1384–1390 (2007).
Gish, R. G. et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 25, 3069–3075 (2007).
Boige, V. et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03–03 trial. Br. J. Cancer 97, 862–867 (2007).
Edeline, J. et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J. Gastroenterol. 15, 713–716 (2009).
Davila, J. A., Duan, Z., McGlynn, K. A. & El-Serag, H. B. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J. Clin. Gastroenterol. 46, 71–77 (2012).
Qin, S. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501–3508 (2013).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Hanahan, D. & Weinberg, A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Villanueva, A. & Llovet, J. M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410–1426 (2011).
Cheng, A. L. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol. 31, 4067–4075 (2013).
Llovet, J. M. et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509–3516 (2013).
Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517–3524 (2013).
Zhu, A. X. et al. EVOLVE-1: phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib [abstract]. J. Clin. Oncol. 32, a172 (2014).
Forner, A. et al. Diagnosis and treatment of hepatocellular carcinoma [Spanish]. Med. Clin. (Barc.) 132, 272–287 (2009).
Reig, M. et al. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology 58, 2023–2031 (2013).
Raoul, J. L., Boucher, E., Rolland, Y. & Garin, E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat. Rev. Gastroenterol. Hepatol. 7, 41–49 (2010).
Sangro, B., Inarrairaegui, M. & Bilbao, J. I. Radioembolization for hepatocellular carcinoma. J. Hepatol. 56, 464–473 (2012).
Riaz, A. et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49, 1185–1193 (2009).
Kulik, L. M. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47, 71–81 (2008).
Salem, R. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138, 52–64 (2010).
Hilgard, P. et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52, 1741–1749 (2010).
Sangro, B. et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54, 868–878 (2011).
Mazzaferro, V. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57, 1826–1837 (2013).
Salem, R. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140, 497–507 (2011).
Sangro, B. et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112, 1538–1546 (2008).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
US National Library of Medicine. ClinicalTrials.gov [online], (2014).
Acknowledgements
The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd; Networked Biomedical Research Centre for Hepatic and Digestive Diseases) is funded by the Instituto de Salud Carlos III. The Instituto de Salud Carlos III has also supported the work of A.F. and J.B. (grants PI11/01830 and PI13/01229).
Author information
Authors and Affiliations
Contributions
A.F., J.B. and J.-L.R. contributed to all stages of the preparation of the manuscript for submission. M.G. made substantial contributions researching data for article, discussion of content, and review/editing of the manuscript before submission.
Corresponding authors
Ethics declarations
Competing interests
A.F. has acted as a consultant for Bayer HealthCare. J.B. has acted as a consultant or in an advisory role for ArQule, Bayer, Biocompatibles, Bristol-Myers Squibb, Celgene, Daiichi-Sankyo, Kowa, Lilly, Novartis, Roche, and Terumo. J.-L.R. has acted as a consultant or in an advisory role for Arqule, Bayer HealthCare, Biocompatibles, Bristol-Myers Squibb, and Merck Serono. M.G. declares no competing interests.
Rights and permissions
About this article
Cite this article
Forner, A., Gilabert, M., Bruix, J. et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11, 525–535 (2014). https://doi.org/10.1038/nrclinonc.2014.122
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.122
This article is cited by
-
ZNF281 inhibits mitochondrial biogenesis to facilitate metastasis of hepatocellular carcinoma
Cell Death Discovery (2023)
-
The immune-chemo-embolization effect of temperature sensitive gold nanomedicines against liver cancer
Nano Research (2023)
-
Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma
Cancer Cell International (2022)
-
A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy
Cell Death Discovery (2022)
-
The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus
Scientific Reports (2022)